PreveCeutical Medical Inc. PRVCF Archives - Page 6 of 6

FridayFeb 09, 2018 10:22 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advancing Work on Novel Delivery for Cannabinoid Therapies

A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021,…

MondayFeb 05, 2018 2:13 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developing Alternative Solutions in Health-Boosting Market

Company offers options to patients seeking immune system-boosting alternatives Novel “scorpion venom” product builds on popular Cuban cancer-fighting therapy Developing a CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures and neurological disorders In an era when a licensed and regulated medical industry provides a secure standard of care for treating ailments but “complementary” or alternative therapies are sought by a number of patients — more than three out of 10 adults, according to the National Institutes of Health’s most recent survey on the subject (http://ibn.fm/sxFbe) — PreveCeutical Medical Inc. (CSE: PREV)…

ThursdayFeb 01, 2018 4:29 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Teams with UniQuest to Develop Novel Cannabinoid Delivery System

Global nasal drug delivery technology market expected to reach $64 billion by 2021 Development of CBD-infused soluble gel for nasal delivery targets range of diseases Clinical benefits of Sol-gel delivery method include a safer, more reliable delivery platform with higher efficacy Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and UniQuest Pty Limited, the main commercialization company of the University of Queensland (UQ), Australia, are expecting 2018 to be an exciting, productive year for joint medical research projects. PreveCeutical Medical, headquartered in Vancouver, British Columbia, has entered into a research and option agreement with the University…

TuesdayJan 30, 2018 1:03 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Details Research and Option Agreement with UniQuest Pty Limited

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning announced and detailed its entry into a research and option agreement with the University of Queensland (“UQ”) and UniQuest Pty Limited, UQ’s main commercialization company. Per the terms of the agreement, the parties intend to conduct a research program aimed at expanding the use of their disulfide linker technology and developing non-addictive analgesics for the treatment of pain. The research program has a targeted start date of March 1, 2018, and is expected to be led by UQ researcher and PreveCeutical Chief Research Officer Dr. Harendra…

WednesdayJan 24, 2018 2:21 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Issues Update on Scorpion Venom Research Program

Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning offered an update on its scorpion venom-derived peptide research and development program, which consists of identifying, extracting and sequencing peptides and proteins isolated from Caribbean blue scorpion venom. Per the update, the program is progressing on schedule through the first of its three distinct phases. As previously noted, PreveCeutical has successfully separated several target scorpion venom-derived peptides and proteins using both one-dimensional gel electrophoresis ("1DE") and two-dimensional gel electrophoresis ("2DE"). Next, the company’s research team aims to sequence the extracted peptides and proteins in order to…

WednesdayJan 24, 2018 12:26 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Enhances Life by Uniting Nature and Science

An ongoing concern in North America, as reported by the Centers for Disease Control and Prevention, is that Americans are only taking advantage of preventive medical services about half as often as they should. Endeavoring to become a pioneer in preventative medicine, health science company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was founded on the belief that, in healthcare, prevention is the best policy, and that nature and science can unite to offer a range of innovative, untapped solutions to address unmet clinical needs. As quoted in a recent article: “PreveCeutical is taking a new look at…

FridayJan 19, 2018 1:27 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Combining Nature and Science to Make Life Better

Company utilizing novel Caribbean blue scorpion venom therapy for immune system boost PreveCeutical seeks new ways to treat cancers, metabolic disorders, pain, infectious diseases and cardiovascular disease Partnership with University of Queensland researchers advances scientific scope of projects In the modern health care industry, disease prevention has taken a commanding role as screenings and regularly scheduled physician visits aim to minimize costs that could otherwise spiral out of control once a chronic condition is established. However, the Centers for Disease Control and Prevention report an ongoing concern that Americans are using preventive services at about half the recommended rate (http://ibn.fm/5IfsA).…

FridayJan 12, 2018 10:44 am

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Receives Initial Coverage from Crystal Equity Research

On January 9, 2018, Crystal Equity Research published an initial report on PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (http://dtn.fm/FYW0w), a biomedical company with a focus on preventative health sciences. Among other highlights, the report noted the company’s recapitalization efforts to fund its development program, as well as the strategic mergers and distribution agreements to address additional markets, including the sports medicine market. The company’s initial product, CELLB9, is an innovative therapy based on blue scorpion venom. The sales from CELLB9 represent the company’s current revenue stream, which helps to balance out research and developmental spending. To view the…

MondayJan 08, 2018 12:31 pm

QualityStocksNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Utilizes Caribbean Blue Scorpion Venom in Proprietary CELLB9®

Health sciences company PreveCeutical Medical (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression. An article discussing this reads: “The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been…

FridayJan 05, 2018 4:26 pm

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is “One to Watch”

Developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression Global market for cancer treatments projected to reach $161.3 billion by 2021 Unique Sol-gel nose-to-brain CBD delivery platform under development to provide clinical relief of various physical disorders Global neuropathic pain market estimated at $8.3 billion by 2024 Proof of concept already demonstrated for dual-gene therapy for type 2 diabetes and obesity Global expenditure for diabetes market in 2016 reached $825 billion PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to…

Site Search

Company Search

Tag: PreveCeutical Medical Inc. PRVCF